SLXN Silexion Earnings per share for the last twelve months

SLXN (Silexion Therapeutics Corp.) - company brandmark

The growth of Silexion Therapeutics Corp (SLXN) is driven by successes in developing RNA-based drugs against KRAS mutations and merger potential. The rolling 12-month earnings per share trend captures the resilience of the trend, with the current value standing at -159.57. The company is minimizing harmful emissions and implementing energy efficiency in its laboratories, while simultaneously automating molecule screening and big data processing using software robots.

SLXN (Silexion Therapeutics Corp) Net earnings per share for the last 12 months history from 08/17/2024 to 11/18/2026

Silexion Therapeutics Corp - analytical breakdowns and key metrics (SLXN)

- current quotes and average value forecast:
Basic company analysis:Silexion Therapeutics Corp. (SLXN)
Mass-produced product of Silexion

Investors must find a balance between operational risks and the actual return on invested capital. Silexion Therapeutics Corp (SLXN) minimizes capital expenditures by outsourcing production and clinical trials. Analyzing the net income per share over the last four quarters reveals the bottom line distributed across the total volume of issuance. This indicator measures the specific efficiency of the business, stripped of the influence of the number of securities. The stability of this value confirms the financial resilience of the model.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months